Reviews - 1wcc mentioned but not cited (1)
- Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Li Y, Zhang J, Gao W, Zhang L, Pan Y, Zhang S, Wang Y. Int J Mol Sci 16 9314-9340 (2015)
Articles - 1wcc mentioned but not cited (3)
- Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. Hall DR, Ngan CH, Zerbe BS, Kozakov D, Vajda S. J Chem Inf Model 52 199-209 (2012)
- Training a scoring function for the alignment of small molecules. Chan SL, Labute P. J Chem Inf Model 50 1724-1735 (2010)
- Open Binding Pose Metadynamics: An Effective Approach for the Ranking of Protein-Ligand Binding Poses. Lukauskis D, Samways ML, Aureli S, Cossins BP, Taylor RD, Gervasio FL. J Chem Inf Model 62 6209-6216 (2022)
Reviews citing this publication (53)
- Vemurafenib: the first drug approved for BRAF-mutant cancer. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Nat Rev Drug Discov 11 873-886 (2012)
- The rise of fragment-based drug discovery. Murray CW, Rees DC. Nat Chem 1 187-192 (2009)
- Fragment-based lead discovery: leads by design. Carr RA, Congreve M, Murray CW, Rees DC. Drug Discov. Today 10 987-992 (2005)
- Adding calorimetric data to decision making in lead discovery: a hot tip. Ladbury JE, Klebe G, Freire E. Nat Rev Drug Discov 9 23-27 (2010)
- Perspectives on NMR in drug discovery: a technique comes of age. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, Luchinat C, Meyer B, Oschkinat H, Peng J, Schwalbe H, Siegal G. Nat Rev Drug Discov 7 738-745 (2008)
- Structural biology and drug discovery. Congreve M, Murray CW, Blundell TL. Drug Discov. Today 10 895-907 (2005)
- Twenty years on: the impact of fragments on drug discovery. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Nat Rev Drug Discov 15 605-619 (2016)
- Universal screening methods and applications of ThermoFluor. Cummings MD, Farnum MA, Nelen MI. J Biomol Screen 11 854-863 (2006)
- From fragment to clinical candidate--a historical perspective. Chessari G, Woodhead AJ. Drug Discov. Today 14 668-675 (2009)
- Structural genomics of protein phosphatases. Almo SC, Bonanno JB, Sauder JM, Emtage S, Dilorenzo TP, Malashkevich V, Wasserman SR, Swaminathan S, Eswaramoorthy S, Agarwal R, Kumaran D, Madegowda M, Ragumani S, Patskovsky Y, Alvarado J, Ramagopal UA, Faber-Barata J, Chance MR, Sali A, Fiser A, Zhang ZY, Lawrence DS, Burley SK. J. Struct. Funct. Genomics 8 121-140 (2007)
- Fragment-based screening using X-ray crystallography and NMR spectroscopy. Jhoti H, Cleasby A, Verdonk M, Williams G. Curr Opin Chem Biol 11 485-493 (2007)
- Fragment-based lead discovery: a chemical update. Erlanson DA. Curr. Opin. Biotechnol. 17 643-652 (2006)
- Hit discovery and hit-to-lead approaches. Keseru GM, Makara GM. Drug Discov. Today 11 741-748 (2006)
- Transforming fragments into candidates: small becomes big in medicinal chemistry. de Kloe GE, Bailey D, Leurs R, de Esch IJ. Drug Discov. Today 14 630-646 (2009)
- Integration of fragment screening and library design. Siegal G, Ab E, Schultz J. Drug Discov. Today 12 1032-1039 (2007)
- Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Blundell TL, Sibanda BL, Montalvão RW, Brewerton S, Chelliah V, Worth CL, Harmer NJ, Davies O, Burke D. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 361 413-423 (2006)
- Fragment-based approaches to enzyme inhibition. Ciulli A, Abell C. Curr. Opin. Biotechnol. 18 489-496 (2007)
- Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. Pellecchia M. Chem. Biol. 12 961-971 (2005)
- Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Winter A, Higueruelo AP, Marsh M, Sigurdardottir A, Pitt WR, Blundell TL. Q. Rev. Biophys. 45 383-426 (2012)
- Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery. Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Foloppe N. Comput Struct Biotechnol J 5 e201302011 (2013)
- Structure-based development of target-specific compound libraries. Orry AJ, Abagyan RA, Cavasotto CN. Drug Discov. Today 11 261-266 (2006)
- Structure-based design of molecular cancer therapeutics. van Montfort RL, Workman P. Trends Biotechnol. 27 315-328 (2009)
- Fragonomics: fragment-based drug discovery. Zartler ER, Shapiro MJ. Curr Opin Chem Biol 9 366-370 (2005)
- The interdependence between screening methods and screening libraries. Shelat AA, Guy RK. Curr Opin Chem Biol 11 244-251 (2007)
- Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Chen H, Zhou X, Wang A, Zheng Y, Gao Y, Zhou J. Drug Discov. Today 20 105-113 (2015)
- NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Barile E, Pellecchia M. Chem. Rev. 114 4749-4763 (2014)
- State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Sheng C, Dong G, Miao Z, Zhang W, Wang W. Chem Soc Rev 44 8238-8259 (2015)
- Integrating molecular design resources within modern drug discovery research: the Roche experience. Stahl M, Guba W, Kansy M. Drug Discov. Today 11 326-333 (2006)
- How good is your screening library? Irwin JJ. Curr Opin Chem Biol 10 352-356 (2006)
- Improving success rates for lead generation using affinity binding technologies. Makara GM, Athanasopoulos J. Curr Opin Biotechnol 16 666-673 (2005)
- Recent applications of protein crystallography and structure-guided drug design. Williams SP, Kuyper LF, Pearce KH. Curr Opin Chem Biol 9 371-380 (2005)
- Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery. Patel D, Bauman JD, Arnold E. Prog. Biophys. Mol. Biol. 116 92-100 (2014)
- Fragment informatics and computational fragment-based drug design: an overview and update. Sheng C, Zhang W. Med Res Rev 33 554-598 (2013)
- High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Wu B, Barile E, De SK, Wei J, Purves A, Pellecchia M. Curr Top Med Chem 15 2032-2042 (2015)
- Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol. Sci. 36 724-736 (2015)
- System-based drug discovery within the human kinome. Bamborough P. Expert Opin Drug Discov 7 1053-1070 (2012)
- Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. Verlinde CL, Fan E, Shibata S, Zhang Z, Sun Z, Deng W, Ross J, Kim J, Xiao L, Arakaki TL, Bosch J, Caruthers JM, Larson ET, Letrong I, Napuli A, Kelly A, Mueller N, Zucker F, Van Voorhis WC, Buckner FS, Merritt EA, Hol WG. Curr Top Med Chem 9 1678-1687 (2009)
- Ligand discovery and virtual screening using the program LIDAEUS. Taylor P, Blackburn E, Sheng YG, Harding S, Hsin KY, Kan D, Shave S, Walkinshaw MD. Br. J. Pharmacol. 153 Suppl 1 S55-67 (2008)
- X-ray crystallography over the past decade for novel drug discovery - where are we heading next? Zheng H, Handing KB, Zimmerman MD, Shabalin IG, Almo SC, Minor W. Expert Opin Drug Discov 10 975-989 (2015)
- Computational chemistry approaches to drug discovery in signal transduction. Fischer PM. Biotechnol J 3 452-470 (2008)
- A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors. Astolfi A, Iraci N, Manfroni G, Barreca ML, Cecchetti V. ChemMedChem 10 957-969 (2015)
- Fragment screening and HIV therapeutics. Bauman JD, Patel D, Arnold E. Top Curr Chem 317 181-200 (2012)
- Fragment-based drug discovery-the importance of high-quality molecule libraries. Bon M, Bilsland A, Bower J, McAulay K. Mol Oncol 16 3761-3777 (2022)
- The role of protein structural analysis in the next generation sequencing era. Yue WW, Froese DS, Brennan PE. Top Curr Chem 336 67-98 (2014)
- Fragment-based inhibitor discovery against β-lactamase. Nichols DA, Renslo AR, Chen Y. Future Med Chem 6 413-427 (2014)
- Recent advances in the structure-based rational design of TNKSIs. Zhan P, Song Y, Itoh Y, Suzuki T, Liu X. Mol Biosyst 10 2783-2799 (2014)
- Scaffold-based design of kinase inhibitors for cancer therapy. Zhang C, Bollag G. Curr. Opin. Genet. Dev. 20 79-86 (2010)
- Structure-based drug design: aiming for a perfect fit. van Montfort RLM, Workman P. Essays Biochem. 61 431-437 (2017)
- Application of Fragment-Based Drug Discovery to Versatile Targets. Li Q. Front Mol Biosci 7 180 (2020)
- NMR-Fragment Based Virtual Screening: A Brief Overview. Singh M, Tam B, Akabayov B. Molecules 23 (2018)
- Protein X-ray Crystallography and Drug Discovery. Maveyraud L, Mourey L. Molecules 25 (2020)
- Concepts and Core Principles of Fragment-Based Drug Design. Kirsch P, Hartman AM, Hirsch AKH, Empting M. Molecules 24 (2019)
- [Fragment-based screening by X-ray structure analysis]. Yamano A. Yakugaku Zasshi 130 335-340 (2010)
Articles citing this publication (97)
- Halogen bonding: an interim discussion. Politzer P, Murray JS. Chemphyschem 14 278-294 (2013)
- The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, Xia B, Beglov D, Vajda S. Nat Protoc 10 733-755 (2015)
- Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design. Lu Y, Wang Y, Zhu W. Phys Chem Chem Phys 12 4543-4551 (2010)
- Molecular docking and ligand specificity in fragment-based inhibitor discovery. Chen Y, Shoichet BK. Nat. Chem. Biol. 5 358-364 (2009)
- Scaffold composition and biological relevance of screening libraries. Shelat AA, Guy RK. Nat. Chem. Biol. 3 442-446 (2007)
- Letter Deconstructing fragment-based inhibitor discovery. Babaoglu K, Shoichet BK. Nat. Chem. Biol. 2 720-723 (2006)
- Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. Matter H, Nazaré M, Güssregen S, Will DW, Schreuder H, Bauer A, Urmann M, Ritter K, Wagner M, Wehner V. Angew. Chem. Int. Ed. Engl. 48 2911-2916 (2009)
- Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Bauman JD, Das K, Ho WC, Baweja M, Himmel DM, Clark AD, Oren DA, Boyer PL, Hughes SH, Shatkin AJ, Arnold E. Nucleic Acids Res. 36 5083-5092 (2008)
- Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Silvestre HL, Blundell TL, Abell C, Ciulli A. Proc. Natl. Acad. Sci. U.S.A. 110 12984-12989 (2013)
- Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. Loving K, Salam NK, Sherman W. J. Comput. Aided Mol. Des. 23 541-554 (2009)
- Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. Ji H, Stanton BZ, Igarashi J, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB. J. Am. Chem. Soc. 130 3900-3914 (2008)
- Fragment-based screening using surface plasmon resonance technology. Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. J Biomol Screen 14 337-349 (2009)
- e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Pihan E, Colliandre L, Guichou JF, Douguet D. Bioinformatics 28 1540-1541 (2012)
- A three-stage biophysical screening cascade for fragment-based drug discovery. Mashalidis EH, Śledź P, Lang S, Abell C. Nat Protoc 8 2309-2324 (2013)
- Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept. Lisurek M, Rupp B, Wichard J, Neuenschwander M, von Kries JP, Frank R, Rademann J, Kühne R. Mol. Divers. 14 401-408 (2010)
- Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. Du QS, Huang RB, Wei YT, Pang ZW, Du LQ, Chou KC. J Comput Chem 30 295-304 (2009)
- Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. Zerbe BS, Hall DR, Vajda S, Whitty A, Kozakov D. J Chem Inf Model 52 2236-2244 (2012)
- Fragment screening: an introduction. Leach AR, Hann MM, Burrows JN, Griffen EJ. Mol Biosyst 2 430-446 (2006)
- Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Antonysamy SS, Aubol B, Blaney J, Browner MF, Giannetti AM, Harris SF, Hébert N, Hendle J, Hopkins S, Jefferson E, Kissinger C, Leveque V, Marciano D, McGee E, Nájera I, Nolan B, Tomimoto M, Torres E, Wright T. Bioorg. Med. Chem. Lett. 18 2990-2995 (2008)
- Detection of secondary binding sites in proteins using fragment screening. Ludlow RF, Verdonk ML, Saini HK, Tickle IJ, Jhoti H. Proc. Natl. Acad. Sci. U.S.A. 112 15910-15915 (2015)
- The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. Vella P, Hussein WM, Leung EW, Clayton D, Ollis DL, Mitić N, Schenk G, McGeary RP. Bioorg. Med. Chem. Lett. 21 3282-3285 (2011)
- In situ click chemistry: a powerful means for lead discovery. Sharpless KB, Manetsch R. Expert Opin Drug Discov 1 525-538 (2006)
- Binding-site assessment by virtual fragment screening. Huang N, Jacobson MP. PLoS ONE 5 e10109 (2010)
- Automated protein-ligand crystallography for structure-based drug design. Mooij WT, Hartshorn MJ, Tickle IJ, Sharff AJ, Verdonk ML, Jhoti H. ChemMedChem 1 827-838 (2006)
- X-ray crystallography: Assessment and validation of protein-small molecule complexes for drug discovery. Cooper DR, Porebski PJ, Chruszcz M, Minor W. Expert Opin Drug Discov 6 771-782 (2011)
- Fragment screening by biochemical assay. Barker J, Courtney S, Hesterkamp T, Ullmann D, Whittaker M. Expert Opin Drug Discov 1 225-236 (2006)
- The multiple roles of computational chemistry in fragment-based drug design. Law R, Barker O, Barker JJ, Hesterkamp T, Godemann R, Andersen O, Fryatt T, Courtney S, Hallett D, Whittaker M. J. Comput. Aided Mol. Des. 23 459-473 (2009)
- FlexNovo: structure-based searching in large fragment spaces. Degen J, Rarey M. ChemMedChem 1 854-868 (2006)
- Design of compound libraries for fragment screening. Blomberg N, Cosgrove DA, Kenny PW, Kolmodin K. J. Comput. Aided Mol. Des. 23 513-525 (2009)
- Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Collins I, Caldwell J, Fonseca T, Donald A, Bavetsias V, Hunter LJ, Garrett MD, Rowlands MG, Aherne GW, Davies TG, Berdini V, Woodhead SJ, Davis D, Seavers LC, Wyatt PG, Workman P, McDonald E. Bioorg. Med. Chem. 14 1255-1273 (2006)
- Effect of electrostatic polarization and bridging water on CDK2-ligand binding affinities calculated using a highly efficient interaction entropy method. Duan L, Feng G, Wang X, Wang L, Zhang Q. Phys Chem Chem Phys 19 10140-10152 (2017)
- EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities. Hsin KY, Morgan HP, Shave SR, Hinton AC, Taylor P, Walkinshaw MD. Nucleic Acids Res. 39 D1042-8 (2011)
- Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. Nazaré M, Matter H, Will DW, Wagner M, Urmann M, Czech J, Schreuder H, Bauer A, Ritter K, Wehner V. Angew. Chem. Int. Ed. Engl. 51 905-911 (2012)
- Identification of a novel ligand binding motif in the transthyretin channel. Lima LM, Silva Vde A, Palmieri Lde C, Oliveira MC, Foguel D, Polikarpov I. Bioorg. Med. Chem. 18 100-110 (2010)
- Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification. Kobayashi M, Retra K, Figaroa F, Hollander JG, Ab E, Heetebrij RJ, Irth H, Siegal G. J Biomol Screen 15 978-989 (2010)
- Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. Zimmermann MO, Lange A, Wilcken R, Cieslik MB, Exner TE, Joerger AC, Koch P, Boeckler FM. Future Med Chem 6 617-639 (2014)
- Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge. Kumar A, Zhang KY. J. Comput. Aided Mol. Des. 26 603-616 (2012)
- Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. Lau WF, Withka JM, Hepworth D, Magee TV, Du YJ, Bakken GA, Miller MD, Hendsch ZS, Thanabal V, Kolodziej SA, Xing L, Hu Q, Narasimhan LS, Love R, Charlton ME, Hughes S, van Hoorn WP, Mills JE. J. Comput. Aided Mol. Des. 25 621-636 (2011)
- Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors. Austin C, Pettit SN, Magnolo SK, Sanvoisin J, Chen W, Wood SP, Freeman LD, Pengelly RJ, Hughes DE. J Biomol Screen 17 868-876 (2012)
- Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition. Englert L, Silber K, Steuber H, Brass S, Over B, Gerber HD, Heine A, Diederich WE, Klebe G. ChemMedChem 5 930-940 (2010)
- Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4. Evensen E, Joseph-McCarthy D, Weiss GA, Schreiber SL, Karplus M. J. Comput. Aided Mol. Des. 21 395-418 (2007)
- Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK. Vinh NB, Simpson JS, Scammells PJ, Chalmers DK. J. Comput. Aided Mol. Des. 26 409-423 (2012)
- Comment A new school for screening. Jhoti H. Nat. Biotechnol. 23 184-186 (2005)
- Advances in fragment-based drug discovery platforms. Orita M, Warizaya M, Amano Y, Ohno K, Niimi T. Expert Opin Drug Discov 4 1125-1144 (2009)
- Direct optical detection in fragment-based screening. Pröll F, Fechner P, Proll G. Anal Bioanal Chem 393 1557-1562 (2009)
- Discovery of novel PTP1B inhibitors with antihyperglycemic activity. Liu Z, Chai Q, Li YY, Shen Q, Ma LP, Zhang LN, Wang X, Sheng L, Li JY, Li J, Shen JK. Acta Pharmacol. Sin. 31 1005-1012 (2010)
- Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei. Begley DW, Hartley RC, Davies DR, Edwards TE, Leonard JT, Abendroth J, Burris CA, Bhandari J, Myler PJ, Staker BL, Stewart LJ. J. Struct. Funct. Genomics 12 63-76 (2011)
- A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline. Chen X, Qin S, Chen S, Li J, Li L, Wang Z, Wang Q, Lin J, Yang C, Shui W. Sci Rep 5 8361 (2015)
- Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogue. Pereira HM, Berdini V, Cleasby A, Garratt RC. FEBS Lett. 581 5082-5086 (2007)
- Development of fragment-based n-FABS NMR screening applied to the membrane enzyme FAAH. Lambruschini C, Veronesi M, Romeo E, Garau G, Bandiera T, Piomelli D, Scarpelli R, Dalvit C. Chembiochem 14 1611-1619 (2013)
- Fragment library design: efficiently hunting drugs in chemical space. Drug Discov Today Technol 7 e147-202 (2010)
- Fragments: past, present and future. Drug Discov Today Technol 7 e147-202 (2010)
- Fragment-based drug discovery using the SHAPES method. Lepre C. Expert Opin Drug Discov 2 1555-1566 (2007)
- Mycobacterium tuberculosis Malate Synthase Structures with Fragments Reveal a Portal for Substrate/Product Exchange. Huang HL, Krieger IV, Parai MK, Gawandi VB, Sacchettini JC. J. Biol. Chem. 291 27421-27432 (2016)
- Streamlining hit discovery and optimization with a yoctoliter scale DNA reactor. Heitner TR, Hansen NJ. Expert Opin Drug Discov 4 1201-1213 (2009)
- Introductory Journal Article Challenges of fragment screening. Joseph-McCarthy D. J. Comput. Aided Mol. Des. 23 449-451 (2009)
- New dimensions of structural proteomics: exploring chemical and biological space. Blundell T. Structure 15 1342-1343 (2007)
- On-chip fragment-based approach for discovery of high-affinity bivalent inhibitors. Miyazaki I, Simizu S, Ishida K, Osada H. Chembiochem 10 838-843 (2009)
- Pharmacophore modeling for protein tyrosine phosphatase 1B inhibitors. Bharatham K, Bharatham N, Lee KW. Arch. Pharm. Res. 30 533-542 (2007)
- An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering. Keedy DA, Hill ZB, Biel JT, Kang E, Rettenmaier TJ, Brandão-Neto J, Pearce NM, von Delft F, Wells JA, Fraser JS. Elife 7 (2018)
- Comprehensive Analysis of Binding Sites in Tubulin. Mühlethaler T, Gioia D, Prota AE, Sharpe ME, Cavalli A, Steinmetz MO. Angew Chem Int Ed Engl 60 13331-13342 (2021)
- Fragmentation-tree density representation for crystallographic modelling of bound ligands. Langer GG, Evrard GX, Carolan CG, Lamzin VS. J. Mol. Biol. 419 211-222 (2012)
- Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. Ruddraraju KV, Aggarwal D, Niu C, Baker EA, Zhang RY, Wu L, Zhang ZY. J Med Chem 63 9212-9227 (2020)
- SkelGen: a general tool for structure-based de novo ligand design. Dean PM, Firth-Clark S, Harris W, Kirton SB, Todorov NP. Expert Opin Drug Discov 1 179-189 (2006)
- Cell-based and virtual fragment screening for adrenergic α2C receptor agonists. Szőllősi E, Bobok A, Kiss L, Vass M, Kurkó D, Kolok S, Visegrády A, Keserű GM. Bioorg. Med. Chem. 23 3991-3999 (2015)
- Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90. Riccardi Sirtori F, Caronni D, Colombo M, Dalvit C, Paolucci M, Regazzoni L, Visco C, Fogliatto G. Eur J Pharm Sci 76 83-94 (2015)
- Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation. Fuglestad B, Kerstetter NE, Bédard S, Wand AJ. ACS Chem Biol 14 2224-2232 (2019)
- Fragment screening of infectious disease targets in a structural genomics environment. Begley DW, Davies DR, Hartley RC, Edwards TE, Staker BL, Van Voorhis WC, Myler PJ, Stewart LJ. Meth. Enzymol. 493 533-556 (2011)
- Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies. Zeifman AA, Stroylov VS, Novikov FN, Stroganov OV, Zakharenko AL, Khodyreva SN, Lavrik OI, Chilov GG. J Mol Model 18 2553-2566 (2012)
- Ligand shape emerges in solvent dipole ordering region at ligand binding site of protein. Murata K, Nagata N, Nakanishi I, Kitaura K. J Comput Chem 31 791-796 (2010)
- Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders. Gladysz R, Cleenewerck M, Joossens J, Lambeir AM, Augustyns K, Van der Veken P. Chembiochem 15 2238-2247 (2014)
- Screening a fragment cocktail library using ultrafiltration. Shibata S, Zhang Z, Korotkov KV, Delarosa J, Napuli A, Kelley AM, Mueller N, Ross J, Zucker FH, Buckner FS, Merritt EA, Verlinde CL, Van Voorhis WC, Hol WG, Fan E. Anal Bioanal Chem 401 1585-1591 (2011)
- Small Molecules Antagonise the MIA-Fibronectin Interaction in Malignant Melanoma. Yip KT, Zhong XY, Seibel N, Pütz S, Autzen J, Gasper R, Hofmann E, Scherkenbeck J, Stoll R. Sci Rep 6 25119 (2016)
- Cocktailed fragment screening by X-ray crystallography of the antibacterial target undecaprenyl pyrophosphate synthase from Acinetobacter baumannii. Thorpe JH, Wall ID, Sinnamon RH, Taylor AN, Stavenger RA. Acta Crystallogr F Struct Biol Commun 76 40-46 (2020)
- Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data. Mohanty B, Williams ML, Doak BC, Vazirani M, Ilyichova O, Wang G, Bermel W, Simpson JS, Chalmers DK, King GF, Mobli M, Scanlon MJ. J. Biomol. NMR 66 195-208 (2016)
- FTree query construction for virtual screening: a statistical analysis. Gerlach C, Broughton H, Zaliani A. J. Comput. Aided Mol. Des. 22 111-118 (2008)
- Frag4Lead: growing crystallographic fragment hits by catalog using fragment-guided template docking. Metz A, Wollenhaupt J, Glöckner S, Messini N, Huber S, Barthel T, Merabet A, Gerber HD, Heine A, Klebe G, Weiss MS. Acta Crystallogr D Struct Biol 77 1168-1182 (2021)
- Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. Jiang L, Zhang X, Zhou Y, Chen Y, Luo Z, Li J, Yuan C, Huang M. RSC Adv 8 28189-28197 (2018)
- Structural and thermodynamic characterization of the binding of isoliquiritigenin to the first bromodomain of BRD4. Yokoyama T, Matsumoto K, Ostermann A, Schrader TE, Nabeshima Y, Mizuguchi M. FEBS J 286 1656-1667 (2019)
- Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library. Huschmann FU, Linnik J, Sparta K, Ühlein M, Wang X, Metz A, Schiebel J, Heine A, Klebe G, Weiss MS, Mueller U. Acta Crystallogr F Struct Biol Commun 72 346-355 (2016)
- News Widening bottlenecks in drug discovery: glimpses from Drug Discovery Technology Europe 2005. Högberg T. Drug Discov. Today 10 820-822 (2005)
- A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. Roy SM, Minasov G, Arancio O, Chico LW, Van Eldik LJ, Anderson WF, Pelletier JC, Watterson DM. J. Med. Chem. 62 5298-5311 (2019)
- A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen). Frederickson M, Selvam IR, Evangelopoulos D, McLean KJ, Katariya MM, Tunnicliffe RB, Campbell B, Kavanagh ME, Charoensutthivarakul S, Blankley RT, Levy CW, de Carvalho LPS, Leys D, Munro AW, Coyne AG, Abell C. Eur J Med Chem 230 114105 (2022)
- Applications of Dissolution-DNP for NMR Screening. Kim Y, Hilty C. Methods Enzymol 615 501-526 (2019)
- Correcting systematic errors in diffraction data with modern scaling algorithms. Aldama LA, Dalton KM, Hekstra DR. Acta Crystallogr D Struct Biol 79 796-805 (2023)
- Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography. Smith CR, Chen D, Christensen JG, Coulombe R, Féthière J, Gunn RJ, Hollander J, Jones B, Ketcham JM, Khare S, Kuehler J, Lawson JD, Marx MA, Olson P, Pearson KE, Ren C, Tsagris D, Ulaganathan T, Van't Veer I, Wang X, Ivetac A. J Med Chem 67 774-781 (2024)
- Discovery of fragments inducing conformational effects in dynamic proteins using a second-harmonic generation biosensor. FitzGerald EA, Butko MT, Boronat P, Cederfelt D, Abramsson M, Ludviksdottir H, van Muijlwijk-Koezen JE, de Esch IJP, Dobritzsch D, Young T, Danielson UH. RSC Adv 11 7527-7537 (2021)
- Discovery of novel druggable pockets on polyomavirus VP1 through crystallographic fragment-based screening to develop capsid assembly inhibitors. Osipov EM, Munawar AH, Beelen S, Fearon D, Douangamath A, Wild C, Weeks SD, Van Aerschot A, von Delft F, Strelkov SV. RSC Chem Biol 3 1013-1027 (2022)
- Fragment screening at AstraZeneca: developing the next generation biophysics fragment set. Lucas SCC, Börjesson U, Bostock MJ, Cuff J, Edfeldt F, Embrey KJ, Eriksson PO, Gohlke A, Gunnarson A, Lainchbury M, Milbradt AG, Moore R, Rawlins PB, Sinclair I, Stubbs C, Storer RI. RSC Med Chem 13 1052-1057 (2022)
- Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study. Galy R, Ballereau S, Génisson Y, Mourey L, Plaquevent JC, Maveyraud L. Pharmaceuticals (Basel) 14 1282 (2021)
- How does a small molecule bind at a cryptic binding site? Shan Y, Mysore VP, Leffler AE, Kim ET, Sagawa S, Shaw DE. PLoS Comput Biol 18 e1009817 (2022)
- Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002. Parker LJ, Taruya S, Tsuganezawa K, Ogawa N, Mikuni J, Honda K, Tomabechi Y, Handa N, Shirouzu M, Yokoyama S, Tanaka A. Acta Crystallogr. D Biol. Crystallogr. 70 392-404 (2014)
- Congresses Microarrays, databases and hard, hard sums. Bousfield D. Drug Discov. Today 10 1594-1597 (2005)
- Modulating drug impact by wrapping target proteins. Fernández A, Scott LR. Expert Opin Drug Discov 2 249-259 (2007)
- Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science. Stuart DD, Guzman-Perez A, Brooijmans N, Jackson EL, Kryukov GV, Friedman AA, Hoos A. Cancer Discov 13 2131-2149 (2023)
- Protein-fragment complex structures derived by NMR molecular replacement. Torres F, Ghosh D, Strotz D, Chi CN, Davis B, Orts J. RSC Med Chem 11 591-596 (2020)
- Structural Analysis and Development of Notum Fragment Screening Hits. Zhao Y, Mahy W, Willis NJ, Woodward HL, Steadman D, Bayle ED, Atkinson BN, Sipthorp J, Vecchia L, Ruza RR, Harlos K, Jeganathan F, Constantinou S, Costa A, Kjær S, Bictash M, Salinas PC, Whiting P, Vincent JP, Fish PV, Jones EY. ACS Chem Neurosci 13 2060-2077 (2022)